dc.creatorFernández, Lucía
dc.creatorCima-Cabal, María Dolores (1)
dc.creatorCatarina Duarte, Ana
dc.creatorRodríguez, Ana
dc.creatorGarcía-Suárez, María del Mar (1)
dc.creatorGarcía, Pilar
dc.date.accessioned2022-03-18T09:35:08Z
dc.date.accessioned2023-03-07T19:35:33Z
dc.date.available2022-03-18T09:35:08Z
dc.date.available2023-03-07T19:35:33Z
dc.date.created2022-03-18T09:35:08Z
dc.identifier2079-6382
dc.identifierhttps://reunir.unir.net/handle/123456789/12676
dc.identifierhttps://doi.org/10.3390/antibiotics10081000
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5906962
dc.description.abstractPneumonia is an acute pulmonary infection whose high hospitalization and mortality rates can, on occasion, bring healthcare systems to the brink of collapse. Both viral and bacterial pneumonia are uncovering many gaps in our understanding of host–pathogen interactions, and are testing the effectiveness of the currently available antimicrobial strategies. In the case of bacterial pneumonia, the main challenge is antibiotic resistance, which is only expected to increase during the current pandemic due to the widespread use of antibiotics to prevent secondary infections in COVID-19 patients. As a result, alternative therapeutics will be necessary to keep this disease under control. This review evaluates the advantages of phage therapy to treat lung bacterial infections, in particular those caused by the Gram-positive bacteria Streptococcus pneumoniae and Staphylococcus aureus, while also highlighting the regulatory impediments that hamper its clinical use and the difficulties associated with phage research.
dc.languageeng
dc.publisherMDPI
dc.relation;vol. 10, nº 8
dc.relationhttps://www.mdpi.com/2079-6382/10/8/1000
dc.rightsopenAccess
dc.subjectantibiotic resistance
dc.subjectendolysins
dc.subjectnew therapies
dc.subjectphage therapy
dc.subjectpneumonia
dc.subjectStaphylococcus aureus
dc.subjectStreptococcus pneumoniae
dc.subjectScopus
dc.subjectJCR
dc.titleGram-positive pneumonia: Possibilities offered by phage therapy
dc.typearticle


Este ítem pertenece a la siguiente institución